[ A23-128] Tebentafusp (uveal melanoma) – Benefit assessment according to §35a Social Code Book
Last updated 01.03.2024
Project no.:
A23-128
Commission:
Commission awarded on 04.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Human leukocyte antigen-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma
Indication of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A23-128_en
| Project no. | Title | Status |
|---|---|---|
| G22-15 | Tebentafusp (uveal melanoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |